Posted on: December 1, 2019 Posted by: earlenehands Comments: 0

Martin E. Gutierrez, MD, on 2nd line treatment options following 1st line PD-L1 targeting agents



Dr. Gutierrez, Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center, Hackensack Meridian Health, shares how he would treat 2nd line patients who previously received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy

source: https://medinaportal.net

Xem thêm các bài viết về Sức Khỏe: https://medinaportal.net/category/suc-khoe/

Categories:

Leave a Comment